CRISPR-Cas Gene Editing: Mechanisms, Applications & Ethics

1. CRISPR-Cas9 Mechanism

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is an adaptive immune system in bacteria. Cas9 nuclease creates double-strand breaks (DSBs) at target DNA directed by guide RNA (gRNA). gRNA consists of: crRNA (20-nt complementary to target) + tracrRNA (scaffold for Cas9 binding), combined as single-guide RNA (sgRNA). PAM requirement: NGG (SpCas9) adjacent to target site — limits targetable sequences. DSB repair: Non-Homologous End Joining (NHEJ) → insertions/deletions (indels) → gene knockout (60–80% efficiency). Homology-Directed Repair (HDR) → precise editing using donor template (5–50% efficiency, cell-cycle dependent).

2. CRISPR Variants & Improvements

Cas12a (Cpf1): T-rich PAM (TTTV), staggered cut, smaller protein. Cas13: RNA-targeting, diagnostic applications (SHERLOCK). Base editors: CBE (C→T) and ABE (A→G) without DSBs — 8th nucleotide window, 50–80% efficiency. Prime editing: "search and replace" using reverse transcriptase fused to Cas9 nickase (pegRNA) — all 12 point mutations, small insertions/deletions without DSBs or donor template. CRISPRi: catalytically dead Cas9 (dCas9) + KRAB repressor for gene silencing. CRISPRa: dCas9 + VP64/p65/Rta for gene activation. Anti-CRISPR proteins: naturally occurring inhibitors enable temporal control. High-fidelity variants: eSpCas9, HiFi Cas9 reduce off-target effects 10–100×.

3. Delivery & Manufacturing

Delivery formats: plasmid DNA (sustained expression, risk of integration), mRNA (transient, no integration risk), RNP (ribonucleoprotein: Cas9 protein + sgRNA, fastest clearance, lowest off-targets). Viral delivery: AAV (4.7 kb limit, low immunogenicity, used in vivo), Lentivirus (stable integration, ex vivo). Non-viral: lipid nanoparticles (LNPs, used for liver targeting — NTLA-2001), electroporation (ex vivo, high efficiency), cell-penetrating peptides. Guide RNA design: on-target scoring (Rule Set 2, DeepCRISPR), off-target prediction (Cas-OFFinder, GUIDE-seq). Manufacturing: GMP-grade Cas9 protein, chemically modified sgRNAs for stability.

4. Therapeutic Applications

FDA/EMA approved: Casgevy (exagamglocel, 2023) — first CRISPR therapy, for sickle cell disease and β-thalassemia. Edits BCL11A enhancer in patient's stem cells, reactivating fetal hemoglobin. Clinical trials (2024–2026): CRISPR Therapeutics CTX001 (blood disorders), Intellia NTLA-2001 (transthyretin amyloidosis — in vivo liver editing, 87% protein reduction), Editas EDIT-101 (Leber congenital amaurosis, retinal in vivo editing). Cancer: allogeneic CAR-T with CRISPR knockout of TCR/MHC (universal donor T cells). Infectious disease: excision of HIV proviral DNA, antiviral against SARS-CoV-2 RNA (Cas13). Agriculture: non-GMO regulatory path in many countries — disease-resistant crops, improved nutrition.

5. Ethics & Regulation

Germline editing: heritable changes — He Jiankui's CCR5-edited twins (2018) widely condemned, resulted in imprisonment. International moratorium on clinical germline editing (NAS, WHO). Somatic editing: non-heritable, broadly accepted for therapeutic purposes. Equity: CRISPR therapies cost $2–3 million per patient (Casgevy) — access concerns. Gene drive: force trait through population (e.g., malaria-resistant mosquitoes) — ecological risk assessment needed. Dual use: bioweapon potential, gain-of-function concerns. Regulation: FDA (biologics license), EMA, case-by-case evaluation. WHO Expert Advisory Committee recommendations. Enhancement vs. therapy: where to draw the line? Designer babies concern vs. preventing genetic disease.

Try it live

Everything above runs in your browser — open Michaelis-Menten Kinetics and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.